Nelson Vergel
Founder, ExcelMale.com
Curated By Nelson Vergel | ExcelMale.com | Updated February 2026
A landmark 2016 randomized controlled trial published in The Journal of Clinical Endocrinology & Metabolism revealed a finding that surprises many men and even some clinicians: estradiol deficiency—not just low testosterone—is the primary driver of hot flashes in men. This distinction has profound implications for how we manage estrogen on TRT and, particularly, for how we approach aromatase inhibitor use. Men who aggressively suppress estradiol with drugs like anastrozole may inadvertently trigger the very symptoms they are trying to avoid.
This guide covers what causes hot flashes in men, the critical role of estradiol in male thermoregulation, why crashed estrogen is more dangerous than most men realize, how to identify and manage vasomotor symptoms on TRT, and what new treatments—including neurokinin receptor antagonists—are on the horizon. Whether you are newly starting TRT or optimizing an existing protocol, understanding this connection between your hormones and body temperature regulation can make a meaningful difference in your quality of life.
Night sweats are the nocturnal counterpart of hot flashes, often severe enough to soak bedding and disrupt sleep. For men on TRT, disrupted sleep from night sweats can compound the fatigue and cognitive issues that testosterone therapy is meant to address, creating a frustrating cycle.
VMS in men are most commonly associated with two clinical scenarios: androgen deprivation therapy (ADT) for prostate cancer, where an estimated 70–80% of men are affected, and male hypogonadism or low testosterone from other causes. However, as we will explore in depth, an often-overlooked third scenario is highly relevant to the TRT community: iatrogenic estradiol suppression from aromatase inhibitor overuse.
When estradiol levels decline—whether due to menopause, ADT, or aromatase inhibitor use—the thermoneutral zone narrows significantly. Even tiny changes in core body temperature can then trigger an exaggerated sweating and vasodilation response, which the person experiences as a hot flash. This is why both menopausal women and hypogonadal men share this symptom: the underlying mechanism is the same.
Under normal conditions, estradiol exerts an inhibitory effect on these KNDy neurons, keeping neurokinin B signaling in check. When estradiol levels fall, this inhibition is lost. The resulting overactivation of neurokinin B signaling through the neurokinin 3 receptor (NK3R) drives hypertrophy of KNDy neurons and triggers inappropriate activation of heat-dissipation pathways—causing hot flashes. Postmortem studies of postmenopausal women have confirmed dramatic KNDy neuron hypertrophy and increased neurokinin B gene expression, and this same mechanism appears to operate in men with low estradiol.
This discovery has been transformative. It explains why both estradiol decline and testosterone decline can cause hot flashes (since testosterone is the precursor to estradiol via aromatization), and it has opened the door to a new class of non-hormonal treatments that target the NK3 receptor directly.
The critical estradiol threshold is around 10 pg/mL. The largest jump in VMS incidence occurred between the 5–9.9 pg/mL group and the 10–14.9 pg/mL group—from 38% to 16% (p < 0.001). This suggests that maintaining estradiol above approximately 10 pg/mL is critical for preventing vasomotor symptoms. Men with estradiol below this threshold are at substantially elevated risk.
High-dose testosterone may independently suppress VMS. In men whose estradiol was blocked by anastrozole, those receiving the highest testosterone dose (10 g gel daily) still showed significantly fewer VMS than the placebo group (16% vs. 43%, p = 0.048), suggesting that testosterone itself may have some direct suppressive effect on hot flashes at supraphysiological levels—though estradiol remains the dominant regulator.
The researchers concluded: “Estradiol deficiency is the key mediator of VMS in hypogonadal men.” They further suggested that aromatizable androgens (testosterone that can convert to estradiol) may have advantages over non-aromatizable androgens in treating symptomatic male hypogonadism.
The problem is that anastrozole is a potent drug with a long pharmacologic effect, and estradiol over-suppression is extremely common. When estradiol is driven below 10 pg/mL—and especially below 5 pg/mL—men may experience not only hot flashes and night sweats, but also joint pain, depression, fatigue, sexual dysfunction, reduced bone mineral density, increased body fat, and impaired insulin sensitivity.
Community members on the ExcelMale forum have shared numerous first-hand accounts of this pattern. One member reported his estradiol dropped to less than 2 pg/mL on anastrozole 0.5 mg three times per week—plummeting from a range of 20–30 pg/mL. He described feeling like a “furnace” throughout the day. When he stopped the anastrozole for a week, the hot flashes subsided. When he resumed it, they returned immediately. A forum moderator responding to this case emphasized that estradiol at 2 pg/mL “is dangerous for your long-term health,” underscoring that estradiol is not a “waste product” but an essential hormone in men.
If you are experiencing these symptoms on TRT, the most important step is to request comprehensive lab work. Essential tests include:
Total testosterone — to verify your levels are in the therapeutic range and not fluctuating excessively between injections. Free testosterone — to assess bioavailable testosterone. Estradiol (sensitive assay / LC-MS/MS) — this is critical. The standard immunoassay estradiol test is unreliable in men at low concentrations. Always request the sensitive estradiol assay for accurate readings. SHBG — sex hormone binding globulin affects the balance between total and free hormones. TSH and free T4 — to rule out thyroid dysfunction as a contributing factor. Prolactin — if other causes are unclear.
Based on the Taylor et al. findings, estradiol levels below 10 pg/mL on the sensitive assay should raise a red flag for vasomotor symptoms. An ideal range for most men on TRT is generally considered to be 20–40 pg/mL, though individual needs may vary. The key is that your clinician should be evaluating estradiol alongside testosterone—not in isolation.
If you are not using AIs but still experiencing VMS, consider whether your testosterone dose is adequate and whether your injection frequency is appropriate. More frequent, smaller injections (e.g., twice-weekly or every-other-day subcutaneous injections) produce more stable testosterone and estradiol levels, reducing the hormonal swings that can trigger vasomotor episodes. Some men find that switching from a biweekly injection schedule to twice-weekly injections makes a significant difference.
Venlafaxine (Effexor): This serotonin-norepinephrine reuptake inhibitor (SNRI) has shown modest benefit in reducing hot flash frequency in men. Typical doses range from 37.5–75 mg daily. Side effects can include nausea, dry mouth, and insomnia.
Gabapentin (Neurontin): Used off-label, gabapentin at 300 mg three times daily has shown some efficacy, though results in men have been modest compared to women. It may also help with sleep quality.
Oxybutynin: Originally developed for overactive bladder, oxybutynin has shown effectiveness for refractory hot flashes. A case report published in the New England Journal of Medicine documented successful treatment of ADT-induced hot flashes with oxybutynin when gabapentin and other therapies had failed. This anticholinergic agent may work through effects on the thermoregulatory center independent of hormonal pathways.
Megestrol acetate: This progestational agent has demonstrated efficacy for hot flashes but carries potential risks including stimulation of prostate cancer growth, making it inappropriate for men with a history of prostate cancer.
Transdermal estradiol: For men on ADT who cannot use testosterone, low-dose transdermal estradiol has been well-validated for reducing VMS. However, gynecomastia remains a common side effect. This approach is generally not needed for men on TRT, where optimizing the testosterone/estradiol balance is the preferred strategy.
Clinical trials have demonstrated that fezolinetant at 45 mg daily reduces moderate-to-severe hot flash frequency by 60–80% and improves sleep quality and overall quality of life. In a notable case published in the New England Journal of Medicine, a man with prostate cancer receiving androgen blockade achieved substantial reduction in refractory hot flashes with fezolinetant when other treatments had failed.
While these NK3R antagonists are currently only approved for menopausal VMS in women, a proof-of-concept trial (the Fezo-ADT Trial) is actively investigating fezolinetant specifically for men with prostate cancer undergoing ADT. If the VMS of ADT and male hypogonadism share the same estrogen-deficiency-driven KNDy neuron mechanism—as all evidence suggests—these drugs could eventually become a transformative option for men as well. For now, off-label use may be considered on a case-by-case basis for men with severe, treatment-refractory hot flashes.
Practical environmental strategies include wearing lightweight, breathable clothing; keeping the bedroom cool (65–68°F) for sleep; using moisture-wicking bedding; and having a fan or cold water nearby when episodes strike. Reducing triggers such as alcohol, caffeine, spicy foods, hot beverages, and tobacco may decrease episode frequency in some men. Stress management through techniques like deep breathing, progressive muscle relaxation, or mindfulness meditation can also help, since sympathetic nervous system activation is a known amplifier of vasomotor responses.
Monitor estradiol with the sensitive assay. Standard estradiol tests are unreliable in men. Always use the LC-MS/MS (sensitive) assay, and be alert to levels below 10 pg/mL as a threshold for vasomotor symptoms.
Optimize, don’t just medicate. Before adding medications for hot flashes, ensure your TRT protocol is optimized: appropriate dose, adequate injection frequency, and—critically—no unnecessary AI use. Many men resolve their VMS simply by adjusting their protocol.
Speak with your doctor if symptoms persist. Hot flashes that continue despite optimized TRT warrant further evaluation. New treatment options are emerging, including NK3 receptor antagonists, and your clinician should be aware of the latest evidence.
Track and report your symptoms. Keep a log of hot flash frequency, severity, and timing in relation to injections and medications. This data is invaluable for working with your clinician to fine-tune your protocol.
Low Estradiol May Cause Hot Flashes and Night Sweats in Men — Nelson Vergel shares the Taylor et al. study showing estradiol deficiency as the primary mediator of vasomotor symptoms in hypogonadal men.
Low Estradiol Increases Hot Flashes and Sweating in Men with Low Testosterone — Detailed discussion of the randomized controlled trial data on estradiol and testosterone’s roles in male VMS.
Hot Flashes and Low E2 — A member shares his experience with estradiol crashing to less than 2 pg/mL on anastrozole, causing severe hot flashes that resolved when the AI was discontinued.
2. Lin KL, Talmor B, Crumbaker M, Joshua AM. A Review of Hot Flash Management in Patients With Prostate Cancer. J Clin Endocrinol Metab. 2025;110(9):2509–2519. [Full Text]
3. Shah S, Pepin A, Jatar S, et al. Bothersome Hot Flashes Following Neoadjuvant Androgen Deprivation Therapy and Stereotactic Body Radiotherapy for Localized Prostate Cancer. Cureus. 2024;16(3):e55729. [Full Text]
4. Punjani N, Bernie H, Salter C, et al. The Utilization and Impact of Aromatase Inhibitor Therapy in Men With Elevated Estradiol Levels on Testosterone Therapy. Sex Med. 2021;9:100378. [Full Text]
5. Qin KR, et al. Could menopause drug fezolinetant show promise for vasomotor symptoms associated with androgen deprivation therapy? Transl Androl Urol. 2024;13(5):920–922. [Full Text]
6. Patel AH, et al. Advent of NK3R Antagonists for the Treatment of Menopausal Hot Flushes: A Narrative Review. BJOG. 2025. doi:10.1111/1471-0528.18338. [Full Text]
7. Rance NE, Dacks PA, et al. Modulation of body temperature and LH secretion by hypothalamic KNDy neurons: a novel hypothesis on the mechanism of hot flushes. Front Neuroendocrinol. 2013;34:211–227. [Full Text]
8. Freedman RR, Krell W. Reduced thermoregulatory null zone in postmenopausal women with hot flashes. Am J Obstet Gynecol. 1999;181:66–70. [Full Text]
9. Lederman S, Ottery FD, Cano A, et al. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. Lancet. 2023;401:1091–1102. [Full Text]
10. Burnett-Bowie SA, McKay EA, Lee H, Leder BZ. Effects of aromatase inhibition on bone mineral density and bone turnover in older men with low testosterone levels. J Clin Endocrinol Metab. 2009;94(12):4785–4792. [Full Text]
Summary
Hot flashes and night sweats—collectively known as vasomotor symptoms (VMS)—are among the most disruptive yet frequently overlooked side effects experienced by men with low testosterone or those on testosterone replacement therapy (TRT). While most men associate hot flashes with menopause in women, research now shows that approximately 70% of men with severe hypogonadism experience vasomotor symptoms, and these episodes can significantly impact sleep quality, cognitive function, social life, and overall wellbeing.A landmark 2016 randomized controlled trial published in The Journal of Clinical Endocrinology & Metabolism revealed a finding that surprises many men and even some clinicians: estradiol deficiency—not just low testosterone—is the primary driver of hot flashes in men. This distinction has profound implications for how we manage estrogen on TRT and, particularly, for how we approach aromatase inhibitor use. Men who aggressively suppress estradiol with drugs like anastrozole may inadvertently trigger the very symptoms they are trying to avoid.
This guide covers what causes hot flashes in men, the critical role of estradiol in male thermoregulation, why crashed estrogen is more dangerous than most men realize, how to identify and manage vasomotor symptoms on TRT, and what new treatments—including neurokinin receptor antagonists—are on the horizon. Whether you are newly starting TRT or optimizing an existing protocol, understanding this connection between your hormones and body temperature regulation can make a meaningful difference in your quality of life.
What Are Vasomotor Symptoms in Men?
Vasomotor symptoms are episodes of sudden, intense heat typically concentrated around the head, neck, chest, and upper back, often accompanied by profuse sweating and visible skin flushing. In men, these episodes generally last between one and five minutes and may be followed by a chilling sensation or cold sweat. Some men experience only occasional episodes, while others report them up to ten or more times per day.Night sweats are the nocturnal counterpart of hot flashes, often severe enough to soak bedding and disrupt sleep. For men on TRT, disrupted sleep from night sweats can compound the fatigue and cognitive issues that testosterone therapy is meant to address, creating a frustrating cycle.
VMS in men are most commonly associated with two clinical scenarios: androgen deprivation therapy (ADT) for prostate cancer, where an estimated 70–80% of men are affected, and male hypogonadism or low testosterone from other causes. However, as we will explore in depth, an often-overlooked third scenario is highly relevant to the TRT community: iatrogenic estradiol suppression from aromatase inhibitor overuse.
The Science: How Hormones Control Your Body’s Thermostat
To understand why low hormones cause hot flashes, you need to understand the concept of the thermoneutral zone—the range of core body temperatures within which neither sweating nor shivering is triggered. In healthy individuals with normal hormone levels, this zone is relatively wide, allowing the body to tolerate small fluctuations in temperature without activating heat-dissipation responses.When estradiol levels decline—whether due to menopause, ADT, or aromatase inhibitor use—the thermoneutral zone narrows significantly. Even tiny changes in core body temperature can then trigger an exaggerated sweating and vasodilation response, which the person experiences as a hot flash. This is why both menopausal women and hypogonadal men share this symptom: the underlying mechanism is the same.
The KNDy Neuron Pathway
Recent neuroscience research has identified the specific brain circuitry responsible for hot flashes. In the hypothalamus, a cluster of neurons called KNDy neurons (named for the neuropeptides they express: Kisspeptin, Neurokinin B, and Dynorphin) serve as a critical link between reproductive hormones and the thermoregulatory center.Under normal conditions, estradiol exerts an inhibitory effect on these KNDy neurons, keeping neurokinin B signaling in check. When estradiol levels fall, this inhibition is lost. The resulting overactivation of neurokinin B signaling through the neurokinin 3 receptor (NK3R) drives hypertrophy of KNDy neurons and triggers inappropriate activation of heat-dissipation pathways—causing hot flashes. Postmortem studies of postmenopausal women have confirmed dramatic KNDy neuron hypertrophy and increased neurokinin B gene expression, and this same mechanism appears to operate in men with low estradiol.
This discovery has been transformative. It explains why both estradiol decline and testosterone decline can cause hot flashes (since testosterone is the precursor to estradiol via aromatization), and it has opened the door to a new class of non-hormonal treatments that target the NK3 receptor directly.
Estradiol Deficiency: The Key Mediator of Male Hot Flashes
The most important study on this topic is the Taylor et al. randomized controlled trial, published in The Journal of Clinical Endocrinology & Metabolism in 2016. This elegantly designed study enrolled 400 healthy men aged 20–50 and used a GnRH agonist (goserelin) to suppress gonadal steroid production, then added back varying doses of testosterone gel—with or without the aromatase inhibitor anastrozole—to isolate the separate effects of testosterone and estradiol on vasomotor symptoms.Key Findings from the Taylor Study
Estradiol deficiency is the primary driver. Men who received testosterone plus anastrozole (which blocked conversion to estradiol) reported VMS at 35% of visits, compared to 26% in men who received testosterone alone (allowing normal aromatization). This statistically significant difference (p = 0.02) directly demonstrated the impact of estradiol deficiency.The critical estradiol threshold is around 10 pg/mL. The largest jump in VMS incidence occurred between the 5–9.9 pg/mL group and the 10–14.9 pg/mL group—from 38% to 16% (p < 0.001). This suggests that maintaining estradiol above approximately 10 pg/mL is critical for preventing vasomotor symptoms. Men with estradiol below this threshold are at substantially elevated risk.
High-dose testosterone may independently suppress VMS. In men whose estradiol was blocked by anastrozole, those receiving the highest testosterone dose (10 g gel daily) still showed significantly fewer VMS than the placebo group (16% vs. 43%, p = 0.048), suggesting that testosterone itself may have some direct suppressive effect on hot flashes at supraphysiological levels—though estradiol remains the dominant regulator.
The researchers concluded: “Estradiol deficiency is the key mediator of VMS in hypogonadal men.” They further suggested that aromatizable androgens (testosterone that can convert to estradiol) may have advantages over non-aromatizable androgens in treating symptomatic male hypogonadism.
The Aromatase Inhibitor Trap: When Estrogen Management Goes Wrong
One of the most clinically relevant implications of this research for the TRT community concerns the use of aromatase inhibitors (AIs) like anastrozole (Arimidex). These drugs are commonly prescribed alongside testosterone to prevent estradiol from rising too high—a legitimate concern in some men who are genetically predisposed to higher aromatization. However, the practice of routinely prescribing AIs to all men on TRT, or of using doses that are too aggressive, remains widespread and potentially harmful.The problem is that anastrozole is a potent drug with a long pharmacologic effect, and estradiol over-suppression is extremely common. When estradiol is driven below 10 pg/mL—and especially below 5 pg/mL—men may experience not only hot flashes and night sweats, but also joint pain, depression, fatigue, sexual dysfunction, reduced bone mineral density, increased body fat, and impaired insulin sensitivity.
Community members on the ExcelMale forum have shared numerous first-hand accounts of this pattern. One member reported his estradiol dropped to less than 2 pg/mL on anastrozole 0.5 mg three times per week—plummeting from a range of 20–30 pg/mL. He described feeling like a “furnace” throughout the day. When he stopped the anastrozole for a week, the hot flashes subsided. When he resumed it, they returned immediately. A forum moderator responding to this case emphasized that estradiol at 2 pg/mL “is dangerous for your long-term health,” underscoring that estradiol is not a “waste product” but an essential hormone in men.
When Are AIs Appropriate?
There is no reason to automatically place every man on an aromatase inhibitor when starting TRT. AIs should be reserved for men who develop genuinely symptomatic elevated estradiol—typically estradiol levels above 60 pg/mL, or between 40–60 pg/mL with symptoms such as breast tenderness, significant water retention, or emotional lability. When AIs are used, the dose should be kept as low as possible (often 0.25–0.5 mg once or twice per week), with careful monitoring of estradiol levels to avoid over-suppression. The goal is hormonal balance, not estradiol elimination.Common Causes of Hot Flashes in Men
Understanding the various causes of male hot flashes is essential for identifying the right treatment approach. The following table outlines the most common causes encountered in clinical practice and in the TRT community.Cause | Mechanism / Notes |
Low Testosterone (Hypogonadism) | Low T leads to low estradiol via reduced aromatization; both contribute to thermoregulatory dysfunction |
Androgen Deprivation Therapy | GnRH agonists, antagonists, or surgical castration for prostate cancer suppress testosterone and estradiol |
Aromatase Inhibitor Overuse | Anastrozole, letrozole, or exemestane can crash estradiol below the critical 10 pg/mL threshold |
TRT Dose Fluctuations | Inconsistent dosing or long injection intervals cause hormonal swings that trigger VMS |
Age-Related Hormone Decline | Gradual decline in testosterone and estradiol with aging (andropause) can narrow the thermoneutral zone |
Thyroid Disorders | Both hyperthyroidism and hypothyroidism can disrupt thermoregulation independently |
Medications | Certain drugs including opioids, GnRH analogs, and some antidepressants can affect hormonal balance |
Stress and Anxiety | Activation of the sympathetic nervous system can trigger or amplify vasomotor episodes |
Recognizing Vasomotor Symptoms and Getting Tested
Hot flashes in men typically present as sudden episodes of warmth or intense heat in the upper body—particularly the face, neck, chest, and back—accompanied by visible flushing, sweating, and sometimes heart palpitations or anxiety. They generally last one to five minutes and end in a cold sweat. Night sweats follow a similar pattern but occur during sleep, often leading to soaked sheets and disrupted rest.If you are experiencing these symptoms on TRT, the most important step is to request comprehensive lab work. Essential tests include:
Total testosterone — to verify your levels are in the therapeutic range and not fluctuating excessively between injections. Free testosterone — to assess bioavailable testosterone. Estradiol (sensitive assay / LC-MS/MS) — this is critical. The standard immunoassay estradiol test is unreliable in men at low concentrations. Always request the sensitive estradiol assay for accurate readings. SHBG — sex hormone binding globulin affects the balance between total and free hormones. TSH and free T4 — to rule out thyroid dysfunction as a contributing factor. Prolactin — if other causes are unclear.
Based on the Taylor et al. findings, estradiol levels below 10 pg/mL on the sensitive assay should raise a red flag for vasomotor symptoms. An ideal range for most men on TRT is generally considered to be 20–40 pg/mL, though individual needs may vary. The key is that your clinician should be evaluating estradiol alongside testosterone—not in isolation.
Treatment and Management Strategies
Optimizing Your TRT Protocol
For most men on TRT who experience hot flashes, the first step is to evaluate and optimize the testosterone protocol itself. If you are using aromatase inhibitors and your estradiol is below 20 pg/mL—and especially below 10 pg/mL—the most important intervention is to reduce or discontinue the AI and allow estradiol to recover. As forum members on ExcelMale have repeatedly confirmed, stopping anastrozole when estradiol is crashed often resolves hot flashes and night sweats within days to weeks.If you are not using AIs but still experiencing VMS, consider whether your testosterone dose is adequate and whether your injection frequency is appropriate. More frequent, smaller injections (e.g., twice-weekly or every-other-day subcutaneous injections) produce more stable testosterone and estradiol levels, reducing the hormonal swings that can trigger vasomotor episodes. Some men find that switching from a biweekly injection schedule to twice-weekly injections makes a significant difference.
Pharmacological Options for Refractory Hot Flashes
When hot flashes persist despite optimized TRT, several medications have demonstrated efficacy. A 2025 review published in The Journal of Clinical Endocrinology & Metabolism by Lin et al. summarized the current evidence for VMS management, noting that hormonal therapies are most effective but non-hormonal options also provide meaningful relief.Venlafaxine (Effexor): This serotonin-norepinephrine reuptake inhibitor (SNRI) has shown modest benefit in reducing hot flash frequency in men. Typical doses range from 37.5–75 mg daily. Side effects can include nausea, dry mouth, and insomnia.
Gabapentin (Neurontin): Used off-label, gabapentin at 300 mg three times daily has shown some efficacy, though results in men have been modest compared to women. It may also help with sleep quality.
Oxybutynin: Originally developed for overactive bladder, oxybutynin has shown effectiveness for refractory hot flashes. A case report published in the New England Journal of Medicine documented successful treatment of ADT-induced hot flashes with oxybutynin when gabapentin and other therapies had failed. This anticholinergic agent may work through effects on the thermoregulatory center independent of hormonal pathways.
Megestrol acetate: This progestational agent has demonstrated efficacy for hot flashes but carries potential risks including stimulation of prostate cancer growth, making it inappropriate for men with a history of prostate cancer.
Transdermal estradiol: For men on ADT who cannot use testosterone, low-dose transdermal estradiol has been well-validated for reducing VMS. However, gynecomastia remains a common side effect. This approach is generally not needed for men on TRT, where optimizing the testosterone/estradiol balance is the preferred strategy.
Emerging Therapies: NK3 Receptor Antagonists
The most exciting development in hot flash treatment is the emergence of neurokinin 3 receptor (NK3R) antagonists—a class of drugs that directly targets the KNDy neuron pathway responsible for thermoregulatory dysfunction. The first of these, fezolinetant (Veozah), was approved by the FDA in May 2023 for moderate-to-severe menopausal vasomotor symptoms. A second agent, elinzanetant (Lynkuet)—a dual NK1/NK3 receptor antagonist—received FDA approval in late 2025.Clinical trials have demonstrated that fezolinetant at 45 mg daily reduces moderate-to-severe hot flash frequency by 60–80% and improves sleep quality and overall quality of life. In a notable case published in the New England Journal of Medicine, a man with prostate cancer receiving androgen blockade achieved substantial reduction in refractory hot flashes with fezolinetant when other treatments had failed.
While these NK3R antagonists are currently only approved for menopausal VMS in women, a proof-of-concept trial (the Fezo-ADT Trial) is actively investigating fezolinetant specifically for men with prostate cancer undergoing ADT. If the VMS of ADT and male hypogonadism share the same estrogen-deficiency-driven KNDy neuron mechanism—as all evidence suggests—these drugs could eventually become a transformative option for men as well. For now, off-label use may be considered on a case-by-case basis for men with severe, treatment-refractory hot flashes.
Lifestyle Strategies for Managing Hot Flashes
While pharmacological management addresses the root hormonal cause, several lifestyle modifications can meaningfully reduce the frequency and severity of hot flashes. Maintaining a healthy body weight is important because excess adipose tissue can alter hormone metabolism and amplify thermoregulatory instability. Regular exercise—particularly resistance training and moderate cardiovascular activity—supports hormonal balance, improves sleep quality, and enhances overall thermoregulation.Practical environmental strategies include wearing lightweight, breathable clothing; keeping the bedroom cool (65–68°F) for sleep; using moisture-wicking bedding; and having a fan or cold water nearby when episodes strike. Reducing triggers such as alcohol, caffeine, spicy foods, hot beverages, and tobacco may decrease episode frequency in some men. Stress management through techniques like deep breathing, progressive muscle relaxation, or mindfulness meditation can also help, since sympathetic nervous system activation is a known amplifier of vasomotor responses.
Key Takeaways for Men on TRT
Estradiol is not the enemy. The research is unequivocal: estradiol is the key mediator of vasomotor symptoms in men. Men need estradiol for bone health, cardiovascular protection, sexual function, cognitive health, and—as this article has emphasized—thermoregulation. Aggressively suppressing estradiol with aromatase inhibitors can cause the very symptoms you are trying to prevent, along with serious long-term health consequences.Monitor estradiol with the sensitive assay. Standard estradiol tests are unreliable in men. Always use the LC-MS/MS (sensitive) assay, and be alert to levels below 10 pg/mL as a threshold for vasomotor symptoms.
Optimize, don’t just medicate. Before adding medications for hot flashes, ensure your TRT protocol is optimized: appropriate dose, adequate injection frequency, and—critically—no unnecessary AI use. Many men resolve their VMS simply by adjusting their protocol.
Speak with your doctor if symptoms persist. Hot flashes that continue despite optimized TRT warrant further evaluation. New treatment options are emerging, including NK3 receptor antagonists, and your clinician should be aware of the latest evidence.
Track and report your symptoms. Keep a log of hot flash frequency, severity, and timing in relation to injections and medications. This data is invaluable for working with your clinician to fine-tune your protocol.
Related ExcelMale Forum Discussions
Explore these community discussions for additional insights and real-world patient experiences:Low Estradiol May Cause Hot Flashes and Night Sweats in Men — Nelson Vergel shares the Taylor et al. study showing estradiol deficiency as the primary mediator of vasomotor symptoms in hypogonadal men.
Low Estradiol Increases Hot Flashes and Sweating in Men with Low Testosterone — Detailed discussion of the randomized controlled trial data on estradiol and testosterone’s roles in male VMS.
Hot Flashes and Low E2 — A member shares his experience with estradiol crashing to less than 2 pg/mL on anastrozole, causing severe hot flashes that resolved when the AI was discontinued.
Key References
1. Taylor AP, Lee H, Webb ML, Joffe H, Finkelstein JS. Effects of Testosterone and Estradiol Deficiency on Vasomotor Symptoms in Hypogonadal Men. J Clin Endocrinol Metab. 2016;101(9):3479–3486. [Full Text]2. Lin KL, Talmor B, Crumbaker M, Joshua AM. A Review of Hot Flash Management in Patients With Prostate Cancer. J Clin Endocrinol Metab. 2025;110(9):2509–2519. [Full Text]
3. Shah S, Pepin A, Jatar S, et al. Bothersome Hot Flashes Following Neoadjuvant Androgen Deprivation Therapy and Stereotactic Body Radiotherapy for Localized Prostate Cancer. Cureus. 2024;16(3):e55729. [Full Text]
4. Punjani N, Bernie H, Salter C, et al. The Utilization and Impact of Aromatase Inhibitor Therapy in Men With Elevated Estradiol Levels on Testosterone Therapy. Sex Med. 2021;9:100378. [Full Text]
5. Qin KR, et al. Could menopause drug fezolinetant show promise for vasomotor symptoms associated with androgen deprivation therapy? Transl Androl Urol. 2024;13(5):920–922. [Full Text]
6. Patel AH, et al. Advent of NK3R Antagonists for the Treatment of Menopausal Hot Flushes: A Narrative Review. BJOG. 2025. doi:10.1111/1471-0528.18338. [Full Text]
7. Rance NE, Dacks PA, et al. Modulation of body temperature and LH secretion by hypothalamic KNDy neurons: a novel hypothesis on the mechanism of hot flushes. Front Neuroendocrinol. 2013;34:211–227. [Full Text]
8. Freedman RR, Krell W. Reduced thermoregulatory null zone in postmenopausal women with hot flashes. Am J Obstet Gynecol. 1999;181:66–70. [Full Text]
9. Lederman S, Ottery FD, Cano A, et al. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. Lancet. 2023;401:1091–1102. [Full Text]
10. Burnett-Bowie SA, McKay EA, Lee H, Leder BZ. Effects of aromatase inhibition on bone mineral density and bone turnover in older men with low testosterone levels. J Clin Endocrinol Metab. 2009;94(12):4785–4792. [Full Text]
